search
Back to results

Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia

Primary Purpose

Schizophrenia

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
risperidone
olanzapine
quetiapine
Sponsored by
Yale University
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Schizophrenia

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: hospitalized for schizophrenia Exclusion Criteria: none

Sites / Locations

    Outcomes

    Primary Outcome Measures

    PANSS
    Retention.

    Secondary Outcome Measures

    EPS, TD.

    Full Information

    First Posted
    October 7, 2005
    Last Updated
    June 5, 2014
    Sponsor
    Yale University
    Collaborators
    National Institute of Mental Health (NIMH)
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00237861
    Brief Title
    Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia
    Official Title
    Effectiveness of Atypical Vs Conventional Antipsychotics
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    undefined (undefined)
    Primary Completion Date
    December 2002 (Actual)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Yale University
    Collaborators
    National Institute of Mental Health (NIMH)

    4. Oversight

    5. Study Description

    Brief Summary
    This study will compare the effectiveness of newer atypical antipsychotics versus older conventional antipsychotics in treating schizophrenia.
    Detailed Description
    At seven participating hospitals, acutely exacerbated patients with schizophrenia were randomly assigned to treatment with antipsychotic from the atypical class vs antipsychotic from the conventional class. Medication choice within class, dose, concomitant medications, and other prescribing decisions were left to the community prescriber. Patients were followed for one year after discharge.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Schizophrenia

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    Single
    Allocation
    Randomized

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    risperidone
    Intervention Type
    Drug
    Intervention Name(s)
    olanzapine
    Intervention Type
    Drug
    Intervention Name(s)
    quetiapine
    Primary Outcome Measure Information:
    Title
    PANSS
    Title
    Retention.
    Secondary Outcome Measure Information:
    Title
    EPS, TD.

    10. Eligibility

    Sex
    All
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: hospitalized for schizophrenia Exclusion Criteria: none
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Scott W Woods, MD
    Organizational Affiliation
    Yale University
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia

    We'll reach out to this number within 24 hrs